Dr. Leen Kawas, CEO of EIT Pharma, Highlights on EASL Congress 2026
KIRKLAND, Wash., June 16, 2026 /PRNewswire/ -- EIT Pharma, Inc. presented new analyses from its lonafarnib development program for Chronic Hepatitis Delta (CHD) at EASL Congress 2026 in Barcelona, Spain, held May 27–30, 2026. The presentations come under the leadership of Chief Executive...
KIRKLAND, Wash., June 16, 2026 /PRNewswire/ -- EIT Pharma, Inc. presented new analyses from its lonafarnib development program for Chronic Hepatitis Delta (CHD) at EASL Congress 2026 in Barcelona, Spain, held May 27–30, 2026. The presentations come under the leadership of Chief Executive...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.